stockrowCerus Corporation
CERS Healthcare Medical Devices
- Revenue
- +6.28%
- EPS
- −2,800.0%
- Free cash flow
- +2,471.3%
- Total debt
- −25.4%
Quarter to September 2026, against a year earlier
Follow CERS
Alert me
Cerus Corporation (CERS) EV/Sales
As of 5 November 2026, Cerus Corporation (CERS) trades at a EV/Sales of 1.7×. Over the past ten years it has ranged from 1.1× (August 2025) to 19.7× (July 2016); the current reading is higher than 15% of that period. That is below the Medical Devices industry median of 2.7× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.7× | 17.72% |
| FY2024 | 1.4× | (33.76%) |
| FY2023 | 2.2× | (35.25%) |
| FY2022 | 3.3× | (51.93%) |
| FY2021 | 6.9× | (24.46%) |
| FY2020 | 9.2× | 56.89% |
| FY2019 | 5.9× | (23.24%) |
| FY2018 | 7.6× | 8.72% |
| FY2017 | 7.0× | (29.14%) |
| FY2016 | 9.9× | (34.76%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 1.9× | (19.42%) |
| Jun 2026 | 2.4× | 64.01% |
| Mar 2026 | 1.5× | (13.22%) |
| Dec 2025 | 1.7× | 22.17% |
| 43 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CERS Cerus Corporation | 1.7× |
| BWAY Brainsway Ltd. Sponsored ADR compare | 2.4× |
| NPCE NeuroPace, Inc. compare | 4.5× |
| DCTH Delcath Systems, Inc. compare | 4.5× |
| MASS 908 Devices Inc. compare | 4.9× |
| SI Shoulder Innovations, Inc. compare | 5.4× |
| SGHT Sight Sciences, Inc. compare | 5.6× |
| SSII SS Innovations International, Inc. compare | 7.1× |
| SENS Senseonics Holdings, Inc. compare | 8.3× |
| Medical Devices industry median | 2.7× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)